LifeMap Sciences, a Subsidiary of BioTime, Announces Release of LifeMap DiscoveryTM Version 1.1 with Enhanced Therapeutic

  LifeMap Sciences, a Subsidiary of BioTime, Announces Release of LifeMap
  DiscoveryTM Version 1.1 with Enhanced Therapeutic Discovery and Commercial
  Utility

Business Wire

ALAMEDA, Calif. -- March 25, 2013

LifeMap Sciences, Inc., a subsidiary of BioTime, Inc. (NYSE MKT: BTX),
announced today the release of LifeMap Discovery^TM version 1.1
(discovery.lifemapsc.com). LifeMap Discovery^TM is a key component in
LifeMap’s integrated database suite, a discovery platform for biomedical and
stem cell research, which also includes GeneCards^®, the leading human gene
database, and MalaCards, the human disease database. LifeMap Discovery^TM
version 1.1 includes significant enhancements of content related to disease
targets for stem cell therapy, cells involved in various diseases (such as
Parkinson’s disease and age related macular degeneration), and a large number
of newly added genes relevant to developmental and stem cell biology.

According to Google Analytics, the integrated database suite had more than
13,000,000 page views and more than 2,000,000 unique visitors in the past 12
months. LifeMap clients and partners include dozens of large, fee-paying
pharmaceutical and biotechnology companies, as well as leading government
patent offices, and its products are used free of charge by scientists at more
than a thousand academic institutions worldwide. The integrated database suite
also provides a technological foundation for thepotential development of
additional LifeMap databases and services that will leverage significant and
growing web traffic. Moreover, the platform drives life scientists to the
LifeMap BioReagents™ portal, which offers cutting-edge stem cell reagents.
LifeMap Discovery™ itself is rapidly becoming utilized by researchers and has
already reached an audience of 10,000 unique visitors since its launch in
November 2012 according to Google Analytics, demonstrating the power of
integration between the databases to drive rapid user-base growth across
various components of the integrated database suite.

LifeMap Discovery™  is a state-of-the-art roadmap of embryonic development and
stem cell biology. The platform integrates embryonic development and stem cell
biology with molecular, cellular, anatomical, and disease-related information,
and provides data-mining capabilities and bioinformatics applications. LifeMap
Discovery™ is a unique and powerful tool for research and discovery in
multiple disciplines, including stem cell biology, developmental biology and
disease mechanisms and etiology. The platform is not only valuable for
clinical applications involving stem differentiation and therapies, it will
continue to be a key to future product development.

LifeMap Discovery^TM is also a key component of LifeMap’s recently announced
therapeutic discovery collaboration with BioTime. The collaboration utilizes
two approaches for identifying stem cell-based therapeutic candidates based on
selected PureStem™ cell lines that are most likely to be useful in developing
cell-based regenerative medicine therapies. The first approach is targeting
selected diseases with large unmet medical needs for which clear and
relatively fast regulatory paths exist. The second approach is screening for
PureStem™ cell lines that are suitable for developing therapies for a wide
range of diseases to be followed with selecting the most commercially
attractive product candidates. By combining the two approaches the companies
expect the collaboration to generate a robust pipeline of high value product
candidates. The two companies will share revenues resulting from
commercialization of successful product candidates that are discovered via the
collaboration and have already filed for patent protection on inventions
jointly made by the teams with an expectation to greatly accelerate the pace
of discovery of potential cures for the deadly degenerative diseases of aging.

LifeMap Discovery^TM version 1.1 new features and information include the
following:

  *Newly mapped developmental paths, added to the previous existing coverage
    of neural crest, motor neurons, blood, endothelium, bone, cartilage,
    adipose, skeletal and smooth muscle, heart, kidney, liver, lung and
    pancreas:

       *Early development of intraembryonic tissues; from zygote through
         epiblast and up to the three germ layers, as well as extraembryonic
         tissues including; placenta, yolk sac, chorion and amnion
       *Development of retinal lineages including; photoreceptors, amacrine
         cells, bipolar cells, horizontal, ganglion and Müller-glial cells
       *Early brain development including neural ectoderm and neural tube, as
         well as the first mapped brain lineage of dopaminergic neurons in the
         substantia nigra, which are involved in Parkinson’s disease
       *Development of brain barriers including the choroid plexus, meninges,
         and endothelial cells related to blood-brain barriers
       *Reproductive system development including ovary, testis, and germ
         cells (male and female gametocytes)
       *Tendon and ligament development

  *Stem cell differentiation into the above mentioned fates:

       *Differentiation into early embryonic tissues mainly to the three germ
         layers (ectoderm, mesoderm, and endoderm) and to early developed
         organs such as the paraxial mesoderm, gut tube, and somites
       *Differentiation protocols related to neural crest, neuronal
         progenitors, motor and dopaminergic neurons, and neurons of the
         peripheral nervous system
       *Differentiation into blood cells and endothelium, adipose tissue,
         bone and cartilage, heart cells, eye photoreceptors and retinal
         pigment epithelium cells, skeletal and smooth muscle cells, kidney,
         liver, lung, pancreas, and thyroid cells

“LifeMap Discovery^TM, Version 1.1, offers a significant leap forward in the
information we offer scientists in many areas of biomedical research such as
developmental and stem cell biology,” said Ronit Shtrichman, PhD, MBA, Vice
President of Biology at LifeMap Sciences. “We will continue to increase our
offering of curated biological data, providing the scientific, biotech and
pharma communities with a key resource for their research and discovery
efforts in the stem cell and regenerative medicine fields.”

“We are delighted to see the rapid improvement of LifeMap Discovery™’s
features and content,” stated Yaron Guan-Golan, Head of Marketing at LifeMap
Sciences. “The recent growth in traffic is a strong signal that LifeMap
Discovery™ answers a clear need for a comprehensive knowledgebase for
developmental biologists and stem cell researchers.”

About LifeMap Sciences, Inc.

LifeMap Sciences’ (www.lifemapsc.com) core technology and business is based on
its integrated database suite, the discovery platform for biomedical and stem
cell research. This platform includes GeneCards^®, the leading human gene
database; LifeMap Discovery™, the database of embryonic development, stem cell
research and regenerative medicine; and MalaCards, the human disease database.
LifeMap Sciences also markets PanDaTox, an innovative, recently developed,
searchable database that can aid in the discovery of new antibiotics and
biotechnologically beneficial products.

In addition to database offerings, LifeMap Sciences is BioTime’s principal
Internet marketing subsidiary for research products, including PureStem™ human
progenitor cell lines, GMP human embryonic stem (hES) cell lines, ESpan™
growth media for progenitor cell lines, and cell differentiation media for
non-therapeutic uses, via its LifeMap BioReagents™ portal. LifeMap Sciences
utilizes its databases as part of its online marketing strategy to reach life
sciences researchers at biotech and pharmaceutical companies and at academic
institutions and research hospitals worldwide.

In a therapeutic discovery collaboration with BioTime, LifeMap’s scientists
utilize LifeMap’s proprietary platform, including LifeMap Discovery™, its stem
cell database along with the GeneCards^® and MalaCards integrated database
suite, to aid in the development of BioTime’s proprietary PureStem™ human
progenitor cell lines into products for the treatment of human diseases,
especially degenerative diseases that might be treatable with cell replacement
therapies. The LifeMap Discovery™ platform is used to select the progenitor
cell lines that are most likely to be useful in developing cell-based
regenerative medicine therapies for a wide range of diseases.

About BioTime, Inc.

BioTime, headquartered in Alameda, California, is a biotechnology company
focused on regenerative medicine and blood plasma volume expanders. Its broad
platform of stem cell technologies is enhanced through subsidiaries focused on
specific fields of application. BioTime develops and markets research products
in the fields of stem cells and regenerative medicine, including a wide array
of proprietary PureStem™ cell lines, HyStem^® hydrogels, culture media, and
differentiation kits. BioTime is developing Renevia™ (formerly known as
HyStem^®-Rx), a biocompatible, implantable hyaluronan and collagen-based
matrix for cell delivery in human clinical applications. BioTime's therapeutic
product development strategy is pursued through subsidiaries that focus on
specific organ systems and related diseases for which there is a high unmet
medical need. BioTime's majority-owned subsidiary Cell Cure Neurosciences Ltd.
is developing therapeutic products derived from stem cells for the treatment
of retinal and neural degenerative diseases. BioTime's subsidiary OrthoCyte
Corporation is developing therapeutic applications of stem cells to treat
orthopedic diseases and injuries. Another subsidiary, OncoCyte Corporation,
focuses on the diagnostic and therapeutic applications of stem cell technology
in cancer, including the diagnostic product PanC-Dx™ currently being developed
for the detection of cancer in blood samples. ReCyte Therapeutics, Inc. is
developing applications of BioTime's proprietary induced pluripotent stem cell
technology to reverse the developmental aging of human cells to treat
cardiovascular and blood cell diseases. BioTime's subsidiary LifeMap Sciences,
Inc. markets GeneCards^®, the leading human gene database, as part of an
integrated database suite that also includes the LifeMap Discovery™ database
of embryonic development, stem cell research and regenerative medicine, and
MalaCards, the human disease database. LifeMap Sciences also markets BioTime
research products and PanDaTox, an innovative, recently developed, searchable
database that can aid in the discovery of new antibiotics and
biotechnologically beneficial products. BioTime Acquisition Corporation is a
new subsidiary being used to acquire the stem cell assets of Geron
Corporation, including patents and other intellectual property, biological
materials, reagents, and equipment for the development of new therapeutic
products for regenerative medicine. BioTime's lead product, Hextend^®, is a
blood plasma volume expander manufactured and distributed in the U.S. by
Hospira, Inc. and in South Korea by CJ CheilJedang Corporation under exclusive
licensing agreements. Additional information about BioTime can be obtained at
www.biotimeinc.com.

Forward-Looking Statements

Statements pertaining to future financial and/or operating results, future
growth in research, technology, clinical development, and potential
opportunities for BioTime and its subsidiaries, along with other statements
about the future expectations, beliefs, goals, plans, or prospects expressed
by management constitute forward-looking statements. Any statements that are
not historical fact (including, but not limited to statements that contain
words such as "will," "believes," "plans," "anticipates," "expects,"
"estimates") should also be considered to be forward-looking statements.
Forward-looking statements involve risks and uncertainties, including, without
limitation, risks inherent in the development and/or commercialization of
potential products, uncertainty in the results of clinical trials or
regulatory approvals, need and ability to obtain future capital, and
maintenance of intellectual property rights. Actual results may differ
materially from the results anticipated in these forward-looking statements
and as such should be evaluated together with the many uncertainties that
affect the business of BioTime and its subsidiaries, particularly those
mentioned in the cautionary statements found in BioTime's Securities and
Exchange Commission filings. BioTime disclaims any intent or obligation to
update these forward-looking statements.

To receive ongoing BioTime corporate communications, please click on the
following link to join our email alert list:
http://phx.corporate-ir.net/phoenix.zhtml?c=83805&p=irol-alerts

Contact:

LifeMap Sciences, Inc.
Kenneth Elsner, COO
781-826-7719
ke@lifemapsc.com
or
BioTime, Inc.
Peter Garcia
Chief Financial Officer
510-521-3390, ext. 367
pgarcia@biotimemail.com
or
Judith Segall
510-521-3390, ext. 301
jsegall@biotimemail.com
 
Press spacebar to pause and continue. Press esc to stop.